EP3765065A2 - Peptides antigéniques dérivés de sécrétogranine v et leurs utilisations pour le diagnostic et le traitement du diabète de type 1 - Google Patents

Peptides antigéniques dérivés de sécrétogranine v et leurs utilisations pour le diagnostic et le traitement du diabète de type 1

Info

Publication number
EP3765065A2
EP3765065A2 EP19711347.5A EP19711347A EP3765065A2 EP 3765065 A2 EP3765065 A2 EP 3765065A2 EP 19711347 A EP19711347 A EP 19711347A EP 3765065 A2 EP3765065 A2 EP 3765065A2
Authority
EP
European Patent Office
Prior art keywords
seq
peptide
cells
cell
hla
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP19711347.5A
Other languages
German (de)
English (en)
Inventor
Roberto Mallone
Joëlle VINH
Yann Verdier
Decio LAKS EIZIRIK
Maikel Luis COLLI
Georgia Afonso
Sergio GONZALEZ-DUQUE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite Libre de Bruxelles ULB
Centre National de la Recherche Scientifique CNRS
Institut National de la Sante et de la Recherche Medicale INSERM
Ecole Superieure de Physique et Chimie Industrielles de Ville Paris
Universite Paris Cite
Original Assignee
Universite Libre de Bruxelles ULB
Centre National de la Recherche Scientifique CNRS
Institut National de la Sante et de la Recherche Medicale INSERM
Ecole Superieure de Physique et Chimie Industrielles de Ville Paris
Universite de Paris
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite Libre de Bruxelles ULB, Centre National de la Recherche Scientifique CNRS, Institut National de la Sante et de la Recherche Medicale INSERM, Ecole Superieure de Physique et Chimie Industrielles de Ville Paris , Universite de Paris filed Critical Universite Libre de Bruxelles ULB
Publication of EP3765065A2 publication Critical patent/EP3765065A2/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation

Definitions

  • the peptide, fusion protein and the immunoconjugate as described herein are particularly suitable for preparing vaccine composition.
  • the term "vaccine composition” is intended to mean a composition which can be administered to humans or to animals in order to induce an immune system response; this immune system response can result in the activation of certain cells, in particular APCs, T lymphocytes and B lymphocytes.
  • the vaccine composition of the present invention comprises an adjuvant.
  • the term“adjuvant” can be a compound that lacks significant activity administered alone but can potentiate the activity of another therapeutic agent.
  • the adjuvant is alum.
  • the CTLA-4 extracellular domain can also recognize and bind CD80 and/or CD86.
  • the extracellular domain may also include fragments or derivatives of CTLA-4 that bind a binds CD 80 and/or CD86.
  • the CTLA-4 molecule may be a fusion protein, where a fusion protein is defined as one or more amino acid sequences joined together using methods well known in the art. The joined amino acid sequences thereby form one fusion protein.
  • the CTLA-4 molecule contains at least a portion of an immunoglobulin, such as the Fc portion of an immunoglobulin.
  • the CTLA-4 molecule is an isolated and purified CTLA-4 molecule.
  • MHC Class I MHC Class II
  • MHC Class II MHC Class II that deliver peptides from different cellular compartments to the cell surface that are recognized by CD8+ and CD4+ T cells, respectively.
  • the TCR is the molecule found on the surface of T cells that is responsible for recognizing antigens bound to MHC molecules.
  • the TCR heterodimer consists of an alpha and beta chain in 95% of T cells, whereas 5% of T cells have TCRs consisting of gamma and delta chains.
  • Engagement of the TCR with antigen and MHC results in activation of its T lymphocyte through a series of biochemical events mediated by associated enzymes, co-receptors, and specialized accessory molecules.
  • Each chain of the TCR is a member of the immunoglobulin superfamily and possesses one N-terminal immunoglobulin (Ig)-variable (V) domain, one Ig- constant (C) domain, a transmembrane region, and a short cytoplasmic tail at the C-terminal end.
  • the constant domain of the TCR consists of short connecting sequences in which a cysteine residue forms a disulfide bond, making a link between the two chains.
  • the structure allows the TCR to associate with other molecules like CD3 which possess three distinct chains (g, d, and e) in mammals and the z-chain. These accessory molecules have negatively charged transmembrane regions and are vital to propagating the signal from the TCR into the cell.
  • the present invention also provides a host cell comprising a nucleic acid encoding for a chimeric antigen receptor or TCR of the present invention.
  • the host cell can be of any cell type, can originate from any type of tissue, and can be of any developmental stage, the host cell is a T cell, e.g. isolated from peripheral blood lymphocytes (PBL) or peripheral blood mononuclear cells (PBMC).
  • PBL peripheral blood lymphocytes
  • PBMC peripheral blood mononuclear cells
  • the T cell may be derived from a T-cell isolated from a subject.
  • the T-cell may be part of a mixed cell population isolated from the subject, such as a population of PBL or whole unfractionated blood.
  • in vitro amplification protocols can be found in Battaglia et ah, J. Immunol. 177:8338-8347 (2006), Putnam et ah, Diabetes 58:652-662 (2009), Gregori et ah, Blood 116:935-944 (2009). While methods for isolating or amplifying suitable numbers of polyclonal Tregs are well known in the art, isolation and/or in vitro expansion of Tregs specific for an antigen of interest such as a b-cell antigen yields more limited cell numbers. Thus, introduction of the desired antigen specificity by transfection or transduction of the CAR or TCR of the present invention into polyclonal Tregs may be envisaged.
  • the predicted translation products were aligned using MUSCLE 3.8 (www.ebi.ac.uk/Tools/msa/muscle), and amino acids neo sequences were defined by comparing the predicted aa sequence of each mRNA iso form with that of the reference mRNA, taking as reference the longest and/or most prevalent mRNA iso form in islets.
  • the overall set of source proteins was enriched for insulin granule products (12/40, 30%; data not shown), namely CHGA, INS, SCG5, PTPRN (IA-2), ATP-binding cassette sub-family C member 8 (ABCC8), proprotein convertase 1 (PCSK1/PC1), urocortin-3 (UCN3), chromogranin B (CHGB), carboxypeptidase E (CPE), proprotein convertase 2 (PCSK2/PC2), secretogranin III (SCG3) and SLC30A8 (Suckale and Solimena, 2010).
  • PCSK1/PC1 proprotein convertase 1
  • UCN3 urocortin-3
  • CPE carboxypeptidase E
  • PCSK2/PC2 proprotein convertase 2
  • SCG3 secretogranin III
  • SLC30A8 secretogranin III
  • IAPP15-17/5-10 and ISL1276-284 representative of the low-medium frequency range detected in peripheral blood (median frequency 1.6x10 -6 and 7.2x1o -6 in T1D patients, respectively; median frequency across all peptides studied 7.6xl0 -6 , interquartile range 2.0xl0 -6 -2.7xl0 -5 ).
  • HLA-A3 + type 1 diabetic and healthy donors gave written informed consent and the study was approved by the local Ethics committees. Blood was drawn into 9 ml sodium heparin tubes and processed, counted and frozen as described (Gonzalez-Duque, Cell Metab 2018).
  • the combinatorial MMr panel was first set up by staining HFA-A3 + PBMCs with the same set of fluorescent streptavidin-labeled MMrs, all loaded with the Flu NP265-273 epitope, which yielded a similar MMr + CD8 + T-cell frequency for all the 15 MMr combination pairs.
  • the same MMr + population was identified for all combinations, except for the BV71 l + BV786 + population which displayed a lower staining intensity and was therefore subsequently used to detect the higher frequency population of positive control Flu NP265-273-reactive CD8 + T cells.
  • Staining was performed for 20 min at 20°C in 20 ml PBS-dasatinib for 10 7 cells with combinatorial double- coded MMr panels, followed, without washing, by CD3-APC-H7 (RRID AB_l 645475), CD8- PE-Cy7 (AB 396852), CD45RA-FITC (AB 395879), CCR7-BV421 (AB 27281 19) monoclonal antibodies and Five/Dead Aqua (ThermoFisher) staining at 4°C for 20 min. After one wash, cells were acquired using a FACSAria III cytometer.
  • HLA-A2- restricted epitopes gave positive hits also for the HLA-A3 restriction, namely KIFlA 86 o- 868 , secretogranins (SCG3i66-i74 and the mRNA splice variant SCG5-009i93-2oi), UCN3 46-56 , GNAS- 03674-83, GNAS-036477 -485).
  • a spliced peptides derived from the fusion of two non-contiguous IA-2 sequences was also identified.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Malgré la notion selon laquelle les lymphocytes T CD8+ humains sont les médiateurs finaux de la destruction des cellules β auto-immunes dans le diabète de type 1 (T1D), aucun de leurs épitopes cibles n'a été mis en évidence comme étant naturellement traité et présenté par des cellules β. Les inventeurs ont donc conduit une étude de découverte d'épitope combinant des stratégies peptidomiques et des stratégies transciptomiques de HLA de classe I. Les cytokines inflammatoires augmentent la présentation de peptides de cellules β in vitro, mettant en parallèle la régulation à la hausse de l'expression de HLA de classe I. Les sources peptidiques comprennent des antigènes de cellules β connus et plusieurs protéines de granules d'insuline. La sécrétogranine V (SCG5/7B2) a été identifiée comme nouvel antigène de cellules β, qui a été traité en épitopes restreints HLA-A2-et HLA-A3- reconnus par la circulation de lymphocytes T CD8+ naïfs chez des donneurs diabétiques et sains de type 1. Des néo-épitopes liés à HLA-A2- ont également été représentés et déterminés comme provenant d'une isoforme d'épissage d'ARNm de SCG5-009 alternative. La présente invention concerne par conséquent des peptides antigéniques dérivés de sécrétogranine V et leurs utilisations pour le diagnostic et le traitement de T1D.
EP19711347.5A 2018-03-16 2019-03-15 Peptides antigéniques dérivés de sécrétogranine v et leurs utilisations pour le diagnostic et le traitement du diabète de type 1 Pending EP3765065A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18305286 2018-03-16
PCT/EP2019/056539 WO2019175380A2 (fr) 2018-03-16 2019-03-15 Peptides antigéniques dérivés de sécrétogranine v et leurs utilisations pour le diagnostic et le traitement du diabète de type 1

Publications (1)

Publication Number Publication Date
EP3765065A2 true EP3765065A2 (fr) 2021-01-20

Family

ID=61832456

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19711347.5A Pending EP3765065A2 (fr) 2018-03-16 2019-03-15 Peptides antigéniques dérivés de sécrétogranine v et leurs utilisations pour le diagnostic et le traitement du diabète de type 1

Country Status (3)

Country Link
US (1) US20210070819A1 (fr)
EP (1) EP3765065A2 (fr)
WO (1) WO2019175380A2 (fr)

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
ATE120454T1 (de) 1988-06-14 1995-04-15 Cetus Oncology Corp Kupplungsmittel und sterisch gehinderte, mit disulfid gebundene konjugate daraus.
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
JP2763958B2 (ja) 1990-06-11 1998-06-11 ネクスター ファーマスーティカルズ，インコーポレイテッド 核酸リガンド
AU8200191A (en) 1990-07-09 1992-02-04 United States of America, as represented by the Secretary, U.S. Department of Commerce, The High efficiency packaging of mutant adeno-associated virus using amber suppressions
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
JP3534749B2 (ja) 1991-08-20 2004-06-07 アメリカ合衆国 アデノウイルスが介在する胃腸管への遺伝子の輸送
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
EP0690452A3 (fr) 1994-06-28 1999-01-07 Advanced Micro Devices, Inc. Mémoire électriquement effaçable et procédé d'effacement
US5635363A (en) 1995-02-28 1997-06-03 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for the detection, quantitation and purification of antigen-specific T cells
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
FR2798128B1 (fr) 1999-09-06 2001-11-16 Inst Nat Sante Rech Med Moyens de detection et de purification de populations lymphocytaires t cd8+ specifiques de peptides presentes dans le contexte hla
MY137552A (en) 2000-07-03 2009-02-27 Bristol Myers Squibb Co Methods for treating rheumatic diseases using a soluble ctla4 molecule
US20040022787A1 (en) 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
US20030170238A1 (en) 2002-03-07 2003-09-11 Gruenberg Micheal L. Re-activated T-cells for adoptive immunotherapy
US8658591B2 (en) * 2008-07-11 2014-02-25 Robert Day Multi-LEU peptides and analogues thereof as selective PACE4 inhibitors and effective antiproliferative agents
WO2010119307A1 (fr) 2009-04-14 2010-10-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédé de stimulation de réponses de lymphocytes t spécifiques d'un antigène à l'aide de cellules dendritiques en co-culture accélérée
CA2930801C (fr) 2010-11-05 2019-05-28 Rinat Neuroscience Corporation Conjugues de polypeptides obtenus par genie biologique, et procede de fabrication correspondants au moyen de transglutaminase
EA029045B1 (ru) 2011-07-08 2018-02-28 Байоджен Хемофилия Инк. Химерные и гибридные полипептиды фактора viii и способы их применения
WO2016141334A2 (fr) * 2015-03-04 2016-09-09 The Regents Of The University Of Colorado Compositions et méthodes de diagnostic et de traitement de maladies auto-immunes
GB201504502D0 (en) * 2015-03-17 2015-04-29 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers

Also Published As

Publication number Publication date
US20210070819A1 (en) 2021-03-11
WO2019175380A2 (fr) 2019-09-19
WO2019175380A3 (fr) 2019-10-31

Similar Documents

Publication Publication Date Title
US20230382997A1 (en) Antigen-binding proteins targeting shared antigens
US11026973B2 (en) Engineered phagocytic receptor compositions and methods of use thereof
US20210061914A1 (en) Antigen-Binding Proteins Targeting Shared Antigens
Brezar et al. Beyond the hormone: insulin as an autoimmune target in type 1 diabetes
US20220162320A1 (en) Multispecific binding proteins
EP3169350B1 (fr) Polypeptide d'interleukine-34 (il-34) isolé destiné à être utilisé dans la prévention du rejet de greffe et de traitement des maladies auto-immunes
US20220213196A1 (en) Antigen-binding proteins targeting shared antigens
Wu et al. Expression and function of immunoglobulin-like transcripts on tolerogenic dendritic cells
WO2016131911A1 (fr) Procédés de diagnostic et de traitement du diabète de type i
Foster et al. Glutamine deamidation does not increase the immunogenicity of C-peptide in people with type 1 diabetes
EP3765065A2 (fr) Peptides antigéniques dérivés de sécrétogranine v et leurs utilisations pour le diagnostic et le traitement du diabète de type 1
EP3765053A2 (fr) Peptides antigéniques dérivés de l'urocortine 3 et leurs utilisations pour le diagnostic et le traitement du diabète de type 1
WO2019175381A1 (fr) Peptides antigéniques dérivés de pcsk2 et leurs utilisations pour le diagnostic et le traitement du diabète de type 1
TWI837109B (zh) 靶向共有抗原之抗原結合蛋白
CN117529492A (zh) 用于治疗的t细胞
WO2022026772A1 (fr) Anticorps multi-spécifiques modifiés et méthodes d'utilisation et procédés de fabrication associés
Amatya Testing Alternative Protein Engineering Strategies for Induction of Functional T Regulatory Cells as a Potential Therapeutic Approach for Type 1 Diabetes
del Rio et al. Immunotherapeutic targeting of LIGHT/LTbR/HVEM pathway fully recapitulates the reduced cytotoxic phenotype of LIGHT-deficient T cells
de Kivit Allergy/Asthma OR. 17. Small-molecule Inhibition of Stat3 Prevents House-Dust-Mite (HDM)-Induced Airway Inflammation by Blocking Lung Production of Th17 and Th2 Cytokines

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20200917

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RAP3 Party data changed (applicant data changed or rights of an application transferred)

Owner name: UNIVERSITE LIBRE DE BRUXELLES

Owner name: ECOLE SUPERIEURE DE PHYSIQUE ET DE CHIMIE INDUSTRIELLES DE LA VILLE DE PARIS

Owner name: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)

Owner name: UNIVERSITE PARIS CITE

Owner name: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)